---
title: "OrbiMed Advisors reports Enliven Therapeutics common stock sale worth $38.02 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290749380.md"
description: "OrbiMed Advisors, a 10% shareholder of Enliven Therapeutics, sold 860,123 common shares on June 22, 2026. The transaction involved sales priced at USD 45 and USD 45.38 per share, totaling approximately $38.02 million. Following these sales, OrbiMed retains beneficial ownership of 6,555,102 indirectly held shares."
datetime: "2026-06-24T23:20:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290749380.md)
  - [en](https://longbridge.com/en/news/290749380.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290749380.md)
generator: "portal-rs"
---

# OrbiMed Advisors reports Enliven Therapeutics common stock sale worth $38.02 million

-   OrbiMed Advisors, a 10% owner of Enliven Therapeutics, reported selling 860,123 common shares on June 22, 2026. \* Sales were priced at USD 45 and USD 45.38 per share. \* OrbiMed reported 6,555,102 shares beneficially owned following the transactions, held indirectly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000947871-26-000653), on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [Enliven Therapeutics CMO Helen Louise Collins reports disposal of 5,000 common shares worth $293,612.17](https://longbridge.com/en/news/296396127.md)
- [OrbiMed Advisors reports $12.67 million Enliven Therapeutics common stock sale](https://longbridge.com/en/news/290116943.md)
- [Eiffage announces availability of H1 2026 results report](https://longbridge.com/en/news/297066901.md)
- [Exmar announces availability of 2026 half-year results release](https://longbridge.com/en/news/296992548.md)
- [IBA publishes H1 2026 results presentation](https://longbridge.com/en/news/297180350.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**